Diagnostic Role and Clinical Association of ASCA and ANCA in Brazilian Patients with Inflammatory Bowel Disease
- 261 Downloads
Anti-Saccharomyces cerevisae antibody (ASCA) and perinuclear anti-neutrophil cytoplasmatic antibody (pANCA) remain the most well-established markers in inflammatory bowel disease (IBD), and both may be associated with disease phenotype.
To determine the utility of ASCA and pANCA as markers in a Brazilian cohort of IBD patients.
Materials And Methods
A total of 90 patients with ulcerative colitis (UC), 77 patients with Crohn’s disease (CD), and 57 healthy individuals were included in the study. ASCA was determined by enzyme-linked immunosorbent assay (ELISA) and pANCA by immunofluorescence assay.
In support of diagnosis of UC, the sensitivity and specificity of pANCA were 51% and 100%, respectively. ASCA (IgA or IgG isotypes) presented sensitivity of 62% and specificity of 93% for CD. The combination of ASCA negativity and pANCA positivity (ASCA−/pANCA+) displayed sensitivity of 43% and specificity of 100% for diagnosis to UC. In CD patients, ASCA+/pANCA− presented sensitivity and specificity of 57% and 93%, respectively. Additionally, ASCA positivity correlated with early age at disease onset and ileal location in CD patients. In UC patients, pANCA positivity was correlated with pancolitis or left colitis.
The results evidenced that low sensitivity of ASCA and pANCA markers limits their use in IBD screening in the general population; however, their specificity may contribute to differentiation between CD and UC in IBD patients. Our study lends further support to the suggestion that serologic assessment identifies different subtypes of IBD.
KeywordsInflammatory bowel disease Ulcerative colitis Crohn’s disease ASCA ANCA Disease phenotype
The authors thanks to Dr. Rhian Phillips for revision of the manuscript.
The authors inform that there are no potential conflicts of interest regarding specific financial interests (personal or institutional).
- 11.Koutrobakis IE, Petinaki E, Mouzas IA. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:449–454.Google Scholar
- 14.Mokrowiecka A, Gasiorowska A, Maleccka-Panas E. Panca and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Hepatogastroenterol. 2007;54:1443–1448.Google Scholar
- 15.Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;11:353–356.Google Scholar
- 19.Cabral VL, Mizputen SJ, Catapani WR. Anti neutrophil cytoplasmatic antibodies in brazilian patients with inflammatory bowel disease. Hepatogastroenterol. 2003;50:412–415.Google Scholar
- 20.Steinwurz F, Scheinberg M. Serologic diagnosis of inflammatory bowel disease (ASCA and ANCA): Evaluation of 70 cases. GED. 2001;20:41–42.Google Scholar
- 23.Buckland MS, Mylonaki M, Rampton D, Longhurst H. Serological markers (Anti Saccharomyces cerevisiae Mannan Antibodies and Antineutrophil Cytoplasmic Antibodies) in inflammatory bowel disease: Diagnostic utility and phenotypic correlation. Clin Diagn Lab Immunol. 2005;12:1328–1330.PubMedGoogle Scholar
- 24.Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA and Anti OmpC in children and young adults with Crohn’s disease and ulcerative colitis: Diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235–2241.CrossRefPubMedGoogle Scholar